Abstract
The traditional model of metastatic progression postulates that the ability to form distant metastases is driven by random mutations in cells of the primary tumor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11(4):R46. https://doi.org/10.1186/bcr2333
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 100(7):3983–3988. https://doi.org/10.1073/pnas.0530291100
Alix-Panabieres C, Pantel K (2014) Technologies for detection of circulating tumor cells: facts and vision. Lab Chip 14(1):57–62. https://doi.org/10.1039/c3lc50644d
Alix-Panabieres C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6(5):479–491. https://doi.org/10.1158/2159-8290.CD-15-1483
Alix-Panabieres C, Bartkowiak K, Pantel K (2016) Functional studies on circulating and disseminated tumor cells in carcinoma patients. Mol Oncol 10(3):443–449. https://doi.org/10.1016/j.molonc.2016.01.004
Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J et al (2014) Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Mol Cancer 13:223. https://doi.org/10.1186/1476-4598-13-223
Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S et al (2012) Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex Cell Search system. Int J Cancer 130(7):1590–1597. https://doi.org/10.1002/ijc.26111
Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD et al (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9(8):997–1007. https://doi.org/10.1158/1541-7786.MCR-10-0490
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544. https://doi.org/10.1038/nbt.2576
Barber AG, Castillo-Martin M, Bonal DM, Jia AJ, Rybicki BA, Christiano AM et al (2015) PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. Cancer Med 4(8):1258–1271. https://doi.org/10.1002/cam4.463
Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449(7165):1003–1007. https://doi.org/10.1038/nature06196
Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M (2014) Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann Transl Med 2(11):109. https://doi.org/10.3978/j.issn.2305-5839.2014.10.04
Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S (2014) Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol 10(10):1751–1765. https://doi.org/10.2217/fon.14.58
Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C et al (2016) Tissue factor induced by epithelial-mesenchymal transition triggers a procoagulant state that drives metastasis of circulating tumor cells. Cancer Res 76(14):4270–4282. https://doi.org/10.1158/0008-5472.CAN-15-2263
Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802. https://doi.org/10.1056/NEJMoa050434
Cannito S, Novo E, Compagnone A, Valfre di Bonzo L, Busletta C, Zamara E et al (2008) Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis. 29(12):2267–2278. https://doi.org/10.1093/carcin/bgn216
Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E et al (2015) Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 75(5):892–901. https://doi.org/10.1158/0008-5472.CAN-14-2613
Celia-Terrassa T, Kang Y (2016) Distinctive properties of metastasis-initiating cells. Genes Dev 30(8):892–908. https://doi.org/10.1101/gad.277681.116
Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y et al (2015) Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer. Oncotarget 6(39):41825–41836. https://doi.org/10.18632/oncotarget.6167
Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17(3):313–319. https://doi.org/10.1038/nm.2304
Coumans FA, Siesling S, Terstappen LW (2013) Detection of cancer before distant metastasis. BMC Cancer 13:283. https://doi.org/10.1186/1471-2407-13-283
De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13(2):97–110. https://doi.org/10.1038/nrc3447
Dinney CPN, Melnikova VO, Pretzsch SM, Garza M, Wu W, Davis DW et al (2014) Heterogeneity of circulating tumor cells isolated from bladder cancer patients using ApoStream and biomarkers of epithelial-mesenchymal transition. J Clin Oncol 32(4_suppl):349. https://doi.org/10.1200/jco.2014.32.4_suppl.349
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767
Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197(4306):893–895
Finlay J, Roberts CM, Lowe G, Loeza J, Rossi JJ, Glackin CA (2015) RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. Biomed Res Int 2015:382745. https://doi.org/10.1155/2015/382745
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19):7011–7021. https://doi.org/10.1158/0008-5472.CAN-04-1364
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. https://doi.org/10.1016/j.stem.2007.08.014
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN et al (2012) Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 11(11):2526–2534. https://doi.org/10.1158/1535-7163.MCT-12-0460
Gorges TM, Kuske A, Rock K, Mauermann O, Muller V, Peine S et al (2016) Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clin Chem 62(11):1504–1515. https://doi.org/10.1373/clinchem.2016.260299
Greulich P, Simons BD (2016) Dynamic heterogeneity as a strategy of stem cell self-renewal. Proc Natl Acad Sci U S A 113(27):7509–7514. https://doi.org/10.1073/pnas.1602779113
Hanssen A, Wagner J, Gorges TM, Taenzer A, Uzunoglu FG, Driemel C et al (2016) Characterization of different CTC subpopulations in non-small cell lung cancer. Sci Rep 6:28010. https://doi.org/10.1038/srep28010
Hegemann M, Stenzl A, Bedke J, Chi KN, Black PC, Todenhofer T (2016) Liquid biopsy: ready to guide therapy in advanced prostate cancer? BJU Int 118(6):855–863. https://doi.org/10.1111/bju.13586
Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz de Luna RI et al (1997) Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 15(1):36–41. https://doi.org/10.1038/ng0197-36
Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D et al (2004) Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23(1):298–302. https://doi.org/10.1038/sj.onc.1206483
Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X (2013) Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS ONE 8(4):e62171. https://doi.org/10.1371/journal.pone.0062171
Hyun KA, Koo GB, Han H, Sohn J, Choi W, Kim SI et al (2016) Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget 7(17):24677–24687. https://doi.org/10.18632/oncotarget.8250
Joosse SA, Gorges TM, Pantel K (2015) Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med 7(1):1–11. https://doi.org/10.15252/emmm.201303698
Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13(3):R59. https://doi.org/10.1186/bcr2896
Karrison TG, Ferguson DJ, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91(1):80–85
Khan MA, Tania M, Wei C, Mei Z, Fu S, Cheng J et al (2015) Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition. Oncotarget 6(23):19580–19591. https://doi.org/10.18632/oncotarget.3973
Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, Fehm T (2014) Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int 2014:415721. https://doi.org/10.1155/2014/415721
Kreso A, Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14(3):275–291. https://doi.org/10.1016/j.stem.2014.02.006
Kulemann B, Liss AS, Warshaw AL, Seifert S, Bronsert P, Glatz T et al (2016) KRAS mutations in pancreatic circulating tumor cells: a pilot study. Tumour Biol 37(6):7547–7554. https://doi.org/10.1007/s13277-015-4589-2
Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178–196. https://doi.org/10.1038/nrm3758
Lander AD, Kimble J, Clevers H, Fuchs E, Montarras D, Buckingham M et al (2012) What does the concept of the stem cell niche really mean today? BMC Biol 10:19. https://doi.org/10.1186/1741-7007-10-19
Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene 24(50):7443–7454. https://doi.org/10.1038/sj.onc.1209091
Li X, Marcondes AM, Gooley TA, Deeg HJ (2010) The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood 116(13):2304–2314. https://doi.org/10.1182/blood-2009-09-242313
Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P et al (2016) Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer 16:168. https://doi.org/10.1186/s12885-016-2192-6
Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ et al (2010) Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 126(3):669–683. https://doi.org/10.1002/ijc.24814
Malara N, Trunzo V, Foresta U, Amodio N, De Vitis S, Roveda L et al (2016) Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment. J Transl Med 14(1):133. https://doi.org/10.1186/s12967-016-0876-y
Marie-Egyptienne DT, Lohse I, Hill RP (2013) Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 341(1):63–72. https://doi.org/10.1016/j.canlet.2012.11.019
Marsden CG, Wright MJ, Pochampally R, Rowan BG (2009) Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods Mol Biol 590:363–375. https://doi.org/10.1007/978-1-60327-378-7_23
Mathenge EG, Dean CA, Clements D, Vaghar-Kashani A, Photopoulos S, Coyle KM et al (2014) Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. Neoplasia 16(11):950–960. https://doi.org/10.1016/j.neo.2014.09.004
Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN et al (2012) Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer 130(4):808–816. https://doi.org/10.1002/ijc.26037
Merindol N, Riquet A, Szablewski V, Eliaou JF, Puisieux A, Bonnefoy N (2014) The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. Blood Cancer J 4:e206. https://doi.org/10.1038/bcj.2014.22
Mitra A, Mishra L, Li S (2015a) EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6(13):10697–10711. https://doi.org/10.18632/oncotarget.4037
Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S (2015b) Cell-surface Vimentin: a mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer 137(2):491–496. https://doi.org/10.1002/ijc.29382
Mohme M, Riethdorf S, Pantel K (2017) Circulating and disseminated tumour cells—mechanisms of immune surveillance and escape. Nat Rev Clin Oncol 14(3):155–167. https://doi.org/10.1038/nrclinonc.2016.144
Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147(3):631–644
Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD et al (2016) Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. Pharmacogenomics J. https://doi.org/10.1038/tpj.2016.62
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110. https://doi.org/10.1038/nature05372
Pantel K, Deneve E, Nocca D, Coffy A, Vendrell JP, Maudelonde T et al (2012) Circulating epithelial cells in patients with benign colon diseases. Clin Chem 58(5):936–940. https://doi.org/10.1373/clinchem.2011.175570
Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, Mavroudis D et al (2014) Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer 14:651. https://doi.org/10.1186/1471-2407-14-651
Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895–902. https://doi.org/10.1038/nrc1232
Park S, Ang RR, Duffy SP, Bazov J, Chi KN, Black PC et al (2014) Morphological differences between circulating tumor cells from prostate cancer patients and cultured prostate cancer cells. PLoS ONE 9(1):e85264. https://doi.org/10.1371/journal.pone.0085264
Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S et al (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25(12):1696–1708. https://doi.org/10.1038/sj.onc.1209327
Pilati P, Mocellin S, Bertazza L, Galdi F, Briarava M, Mammano E et al (2012) Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol 19(2):402–408. https://doi.org/10.1245/s10434-011-2132-2
Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J et al (2016) Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. Ann Surg 264(6):1073–1081. https://doi.org/10.1097/SLA.0000000000001600
Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM et al (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18(5):510–523. https://doi.org/10.1016/j.ccr.2010.10.012
Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106(5). https://doi.org/10.1093/jnci/dju066
Riaz M, Sieuwerts AM, Look MP, Timmermans MA, Smid M, Foekens JA et al (2012) High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Res 14(5):R123. https://doi.org/10.1186/bcr3317
Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR et al (2014) Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74(6):1645–1650. https://doi.org/10.1158/0008-5472.CAN-13-1739
Satelli A, Brownlee Z, Mitra A, Meng QH, Li S (2015a) Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem 61(1):259–266. https://doi.org/10.1373/clinchem.2014.228122
Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ et al (2015b) Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899–906. https://doi.org/10.1158/1078-0432.CCR-14-0894
Schilling D, Todenhofer T, Hennenlotter J, Schwentner C, Fehm T, Stenzl A (2012) Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol. 9(8):448–463. https://doi.org/10.1038/nrurol.2012.136
Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T et al (2013) Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 7(5):976–986. https://doi.org/10.1016/j.molonc.2013.07.007
Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K et al (2013) Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 133(9):2165–2171. https://doi.org/10.1002/ijc.28230
Shipitsin M, Polyak K (2008) The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 88(5):459–463. https://doi.org/10.1038/labinvest.2008.14
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118(6):2111–2120. https://doi.org/10.1172/JCI34401
Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34):4741–4751. https://doi.org/10.1038/onc.2010.215
Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ et al (2013) Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57(4):1458–1468. https://doi.org/10.1002/hep.26151
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. https://doi.org/10.1038/nrc822
Todenhofer T, Hennenlotter J, Faber F, Wallwiener D, Schilling D, Kuhs U et al (2015) Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer. Prostate 75(6):637–645. https://doi.org/10.1002/pros.22947
Todenhofer T, Hennenlotter J, Dorner N, Kuhs U, Aufderklamm S, Rausch S et al (2016) Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients. J Cancer Res Clin Oncol 142(5):1013–1020. https://doi.org/10.1007/s00432-016-2129-0
Todenhofer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME et al (2017) AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate. J Urol 197(1):135–142. https://doi.org/10.1016/j.juro.2016.06.094
Uhr JW, Pantel K (2011) Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 108(30):12396–12400. https://doi.org/10.1073/pnas.1106613108
Valladares-Ayerbes M, Blanco-Calvo M, Reboredo M, Lorenzo-Patino MJ, Iglesias-Diaz P, Haz M et al (2012) Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int J Mol Sci 13(4):4367–4387. https://doi.org/10.3390/ijms13044367
Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A et al (2010) Circulating tumour cell detection: a direct comparison between the Cell Search System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 102(2):276–284. https://doi.org/10.1038/sj.bjc.6605472
Vanharanta S, Massague J (2013) Origins of metastatic traits. Cancer Cell 24(4):410–421. https://doi.org/10.1016/j.ccr.2013.09.007
Vesuna F, van Diest P, Chen JH, Raman V (2008) Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367(2):235–241. https://doi.org/10.1016/j.bbrc.2007.11.151
Vishnoi M, Peddibhotla S, Yin W, Scamardo AT, George GC, Hong DS et al (2015) The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep 5:17533. https://doi.org/10.1038/srep17533
Weissenstein U, Schumann A, Reif M, Link S, Toffol-Schmidt UD, Heusser P (2012) Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer 12:206. https://doi.org/10.1186/1471-2407-12-206
Werner S, Pantel K (2017) Tracing the seeds in the soil. Clin Chem. https://doi.org/10.1373/clinchem.2017.274290
Werner S, Stenzl A, Pantel K, Todenhofer T (2017) Expression of epithelial mesenchymal transition and cancer stem cell markers in circulating tumor cells. Adv Exp Med Biol 994:205–228. https://doi.org/10.1007/978-3-319-55947-6_11
Wu S, Liu S, Liu Z, Huang J, Pu X, Li J et al (2015) Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS ONE 10(4):e0123976. https://doi.org/10.1371/journal.pone.0123976
Wushou A, Hou J, Zhao YJ, Shao ZM (2014) Twist-1 up-regulation in carcinoma correlates to poor survival. Int J Mol Sci 15(12):21621–21630. https://doi.org/10.3390/ijms151221621
Yang MH, Imrali A, Heeschen C (2015) Circulating cancer stem cells: the importance to select. Chin J Cancer Res 27(5):437–449. https://doi.org/10.3978/j.issn.1000-9604.2015.04.08
Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF et al (2016) Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res 76(4):818–830. https://doi.org/10.1158/0008-5472.CAN-15-0977
Yi S, Yang ZL, Miao X, Zou Q, Li J, Liang L et al (2014) N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas. Pathol Res Pract 210(6):363–368. https://doi.org/10.1016/j.prp.2014.01.014
Yoshida GJ, Saya H (2016) Therapeutic strategies targeting cancer stem cells. Cancer Sci 107(1):5–11. https://doi.org/10.1111/cas.12817
Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC et al (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345(6193):216–220. https://doi.org/10.1126/science.1253533
Zelenko Z, Gallagher EJ, Tobin-Hess A, Belardi V, Rostoker R, Blank J et al (2017) Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression. Oncogene 36(10):1394–1403. https://doi.org/10.1038/onc.2016.305
Zhang P, Sun Y, Ma L (2015) ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14(4):481–487. https://doi.org/10.1080/15384101.2015.1006048
Zhu QQ, Ma C, Wang Q, Song Y, Lv T (2016) The role of TWIST1 in epithelial-mesenchymal transition and cancers. Tumour Biol 37(1):185–197. https://doi.org/10.1007/s13277-015-4450-7
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Todenhöfer, T., Pantel, K., Stenzl, A., Werner, S. (2020). Pathophysiology of Tumor Cell Release into the Circulation and Characterization of CTC. In: Schaffner, F., Merlin, JL., von Bubnoff, N. (eds) Tumor Liquid Biopsies. Recent Results in Cancer Research, vol 215. Springer, Cham. https://doi.org/10.1007/978-3-030-26439-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-26439-0_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-26438-3
Online ISBN: 978-3-030-26439-0
eBook Packages: MedicineMedicine (R0)